Watch COGT. Know when insiders buy.
One email the day a filing lands. Free.
COGT
Cogent Biosciences, Inc.
31.31
−0.12 −0.38%
USD · close Oct 22
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
36
FLAG · insiders 25, shorts 46
Insiders, 90 days
−$1.7M
net selling · 0 buys, 2 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $5.4BP/E —DIV YIELD —FCF YIELD -5.69%REV TTM —NET INCOME −$377.2MNET DEBT $42.3M52W 14.13 – 42.84SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$102.6M | −$96.4M | — | -0.52 | −$77.3M | $370K | −$77.6M | Aug 10 |
| Q1 2026 · Mar 31 | — | — | — | −$103.6M | −$97.4M | — | -0.53 | −$86.9M | $449K | −$87.3M | Aug 10 |
| Q4 2025 · Dec 31derived | — | — | — | −$99.5M | −$102.5M | — | -0.61 | −$79.1M | $811K | −$79.9M | Feb 17 |
| Q3 2025 · Sep 30 | — | — | — | −$83.4M | −$80.9M | — | -0.50 | −$64.3M | $65K | −$64.4M | Nov 7 |
| Q2 2025 · Jun 30 | — | — | — | −$75.6M | −$73.5M | — | -0.53 | −$54.5M | $131K | −$54.7M | Aug 10 |
| Q1 2025 · Mar 31 | — | — | — | −$74.9M | −$72M | — | -0.52 | −$66.5M | $547K | −$67.1M | Aug 10 |
| Q4 2024 · Dec 31derived | — | — | — | −$73.7M | −$67.9M | — | -0.50 | −$60.6M | $75K | −$60.7M | Feb 17 |
| Q3 2024 · Sep 30 | — | — | — | −$75.4M | −$70.6M | — | -0.52 | −$52M | $280K | −$52.3M | Nov 7 |
| Q2 2024 · Jun 30 | — | — | — | −$64.4M | −$59M | — | -0.43 | −$42.7M | $148K | −$42.8M | Nov 7 |
| Q1 2024 · Mar 31 | — | — | — | −$62.4M | −$58.3M | — | -0.49 | −$52.5M | $70K | −$52.6M | Nov 7 |
| Q4 2023 · Dec 31derived | — | — | — | −$58.2M | −$54.4M | — | -0.15 | −$44.1M | $315K | −$44.4M | Feb 17 |
| Q3 2023 · Sep 30 | — | — | — | −$59.6M | −$55.4M | — | -0.64 | −$38M | $121K | −$38.1M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$333.4M | −$328.9M | — | -2.16 | −$264.4M | $1.6M | −$266M | — | — |
| FY2024 · to Dec 31 | — | — | −$275.9M | −$255.9M | — | -1.94 | −$207.8M | $573K | −$208.4M | — | — |
| FY2023 · to Dec 31 | — | — | −$208.1M | −$192.4M | — | -1.94 | −$153.6M | $2.8M | −$156.4M | — | — |
| FY2022 · to Dec 31 | — | — | −$147.8M | −$140.2M | — | -1.73 | −$118.6M | $6.9M | −$125.5M | — | — |
| FY2021 · to Dec 31 | — | — | −$75.6M | −$72.3M | — | -1.87 | −$58.8M | $1.7M | −$60.5M | — | — |
| FY2020 · to Dec 31 | — | — | −$82.2M | −$74.8M | — | -16.17 | −$35.9M | — | — | — | — |
Every number comes from Cogent Biosciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.